Frontlight ResearchEarly access
TerminatedPhase 2
L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma
Key facts
- Who runs it
- Quanli Gao
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 9 people enrolled
- Started
- 1 Jul 2021
- Ended
- 2 Jul 2024
- Type of study
- Interventional
- Treatments tested
- Tislelizumab
- Record updated
- 3 July 2024
- Why it stopped
- Slow enrollment
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Pathological confirmed melanoma 2. Advanced stage confirmed by radiological examination 3. Untreated 4. ECOG PS 0-1 6. Good organ function 7. No other severe diseases such as autoimmune disease, organ transplant, chronic infection
- Other tumor disease
Who cannot take part
- Sensitive to drug or ingredients
- Active infection
- Active HBV or HCV infection
- HIV infection
- Autoimmune disease
- Severe mental disorders
- Sever disfunction of heart, liver and kidney
- Symptomatic brain metastases
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main purpose of this study is to evaluate the safety and effectiveness of liquid tumor infiltrating lymphocytes (L-TIL) combined with tislelizumab as the first-line treatment in patients with advanced malignant melanoma. This study plan to include stage III or IV unresectable or metastatic cutaneous or acral malignant melanoma patients, treat with L-TIL 4 cycles with each infusion (3 -10) x10*9/m2 cells, combined with tislelizumab 200mg, iv, Q3W. It is expected that 30 patients will be enrolled in this study.
The group in the trial
- L-TIL and TislelizumabTreatment being tested
L-TIL(3-10)x10\*9/m2, Q3W, 4 cycles Tislelizumab 200mg, iv, Q3W, 1 year
Treatment: Tislelizumab
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 3 July 2024